All In Biotech

Drug Trial Radar · NCT05646524

Study of Efficacy and Safety of NM8074 in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

A Phase II, Open-Label Study of NM8074 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 19, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Aug 2027

Study completion Sep 2028

Sponsor

Lead sponsor
NovelMed TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • NM8074Drug

    NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to Study Day 105
  2. Number of Participants with Antidrug Antibodies (ADAs) to NM8074Time frame: Up to Study Day 105
  3. Change from Baseline or Percent Change from Baseline in Hemoglobin (Hgb) LevelsTime frame: Up to Study Day 105
  4. Change from Baseline or Percent Change from Baseline in Lactate Dehydrogenase (LDH) LevelsTime frame: Up to Study Day 105
  5. Change from Baseline or Percent Change from Baseline in Number of Packed Red Blood Cell (pRBC) TransfusionsTime frame: Up to Study Day 105
  6. Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Levels of MAC via Classical Pathway (CP) of Complement ActivityTime frame: Up to Study Day 105
  7. Percent Change from Baseline in Levels of Complement Component C3b via Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Levels of C3b via Classical Pathway (CP) of Complement ActivityTime frame: Up to Study Day 105

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.